171515-67-6

Basic information

• Product Name: 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde
• Synonyms: 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde
• CAS NO: 171515-67-6
• Molecular Weight: 628.776
• Mol File: 171515-67-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde(171515-67-6)
• EPA Substance Registry System: 2-n-butyl-1-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carbaldehyde(171515-67-6)

Safety Data

• Hazardous Substances Data: 171515-67-6(Hazardous Substances Data)

Upstream product

• 155272-73-4 2-bromo-3-(1-methylethoxy)-2-propenal 
• 918962-64-8 N-{[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}pentaneamidine 
• 36437-19-1 2-chloromalonaldehyde 
• 133051-88-4 N-(triphenylmethyl)-5-<4'-(bromomethyl)biphenyl-2-yl>tetrazole 
• 139742-78-2 4⁽⁵⁾-bromo-2-butyl-1H-imidazole-5⁽⁴⁾-carboxaldehyde 

Downstream Products

• 133910-00-6 2-n-Butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-carboxaldehyde 

Relevant articles and documents

A process for the preparation of losartan derivatives by chlorination and reduction of the respective 1H-imidazole-5-carbaldehydes

The invention provides a process for the preparation of a sartan derivative of formula (I): wherein R = C2-C7 straight or branched alkyl or C3-C9 cycloalkyl, or a pharmaceutically acceptable salt thereof, comprising the steps of chlorinating and reducing, in any order, a compound of formula (III): wherein R is defined as above to form a compound of formula (VI), wherein R is defined as above and then deprotecting said compound of formula (VI) to obtain the sartan derivative of formula (I), and optionally converting said sartan derivative into one of its pharmaceutically acceptable salts. A preferred embodiment of this invention is a process for the preparation of losartan and, particularly, its potassium salt.